Humanoid Global Invests CAD $150,000 in MBody AI to Advance Robotics Intelligence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Globenewswire
- Strategic Investment: Humanoid Global has completed a CAD $150,000 investment in MBody AI, aimed at supporting the deployment of autonomous systems across multiple industries, thereby advancing the commercialization of robotics intelligence.
- Cost Savings: MBody AI's technology enables clients to achieve up to 90% labor cost savings, indicating its strong competitive edge and broad applicability in the enterprise market.
- Industry Leadership: MBody AI's platform is widely adopted by Fortune 500 companies, showcasing its maturity in operating within high-traffic environments, further solidifying its leadership position in the autonomous robotics sector.
- Future Growth Potential: Humanoid Global's investment not only provides financial backing but also strategic consulting to help MBody AI expand its market share, signaling promising prospects for widespread applications in healthcare, logistics, and other sectors.
Analyst Views on MBAI
About MBAI
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
